keyword
MENU ▼
Read by QxMD icon Read
search

chemotherapy vomiting

keyword
https://www.readbyqxmd.com/read/29764827/not-so-mass-effect-finding-of-a-remarkable-incidentaloma-in-a-teenager-with-neurofibromatosis
#1
Daniel John Keen, Hannah Norman-Bruce, Salah Mansy
A 13-year-old boy with neurofibromatosis type 1 presented to the emergency department twice in a fortnight with moderate intermittent abdominal pain, radiating to the back and associated with nausea and vomiting. He examined as a well child with a soft abdomen and minimal tenderness. A history of constipation was identified but he failed to respond to a trial of laxatives. Subsequent ultrasound abdomen demonstrated a large mass surrounding the porta hepatis. MRI further characterised a focal, non-aggressive lesion extending from his liver, encapsulating his pancreas, portal vessels and laterally displacing his spleen and left kidney...
May 14, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29764184/efficacy-of-the-combination-neurokinin-1-receptor-antagonist-palonosetron-and-dexamethasone-compared-to-others-for-the-prophylaxis-of-chemotherapy-induced-nausea-and-vomiting-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#2
Ronald Chow, May Tsao, Leonard Chiu, Marko Popovic, Milica Milakovic, Henry Lam, Carlo DeAngelis
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV), a common side effect of chemotherapy, can substantially impair a patient's quality of life, interfere with a patient's compliance with anticancer therapy, and result in the manifestation of adverse events such as electrolyte imbalance, dehydration and malnutrition. The most recent guidelines published by the Multinational Association of Supportive Care in Cancer (MASCC) and European Society of Medical Oncology (ESMO) recommend the combination of dexamethasone (DEX), a 5-hydroxytrypatmine-3 receptor antagonist (5-HT3RA), preferably palonosetron (PALO), and a neurokinin-1 receptor antagonist (NK1RA) for prophylactic treatment of CINV in patients receiving highly emetogenic chemotherapy (HEC)...
April 2018: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29764183/a-pilot-study-with-palonosetron-in-the-prophylaxis-of-radiation-induced-nausea-and-vomiting
#3
Vithusha Ganesh, Leah Drost, Carlo DeAngelis, Bo Angela Wan, Mark Pasetka, Stephanie Chan, Liying Zhang, May Tsao, Elizabeth Barnes, Natalie Pulenzas, Hans Chung, Pearl Zaki, Caitlin Yee, Edward Chow
BACKGROUND: Palonosetron is an effective antiemetic in chemotherapy-induced nausea and vomiting (CINV), but has yet to be studied in the radiation setting. The purpose of the present study was to investigate the efficacy and safety of palonosetron in the prophylaxis of radiation-induced nausea and vomiting (RINV). METHODS: Patients without existing nausea and vomiting undergoing palliative radiotherapy to sites with emetic risk were prescribed palonosetron 0.5 mg orally before the start of radiation treatment, and every other day until completion of treatment...
April 2018: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29756515/effects-of-polaprezinc-on-gastric-mucosal-damage-and-neurotransmitters-in-a-rat-model-of-chemotherapy-induced-vomiting
#4
Zhao Yang Liu, Wen Bo Xie, Ming Ru Li, Nan Teng, Xiao Liang, Zi Qiang Zhang
Objective To investigate the effects of polaprezinc (PZ) on cyclophosphamide (CTX)- or cisplatin (DDP)-induced gastric mucosal injury and on a rat model of neurotransmitter-mediated vomiting. Methods Sprague-Dawley rats were divided at random into Control, CTX, DDP, PZ+CTX, and PZ+DDP groups. After 20 days, brain tissues and sera were analyzed for the levels of dopamine (DA), 5-hydroxytryptamine (5-HT), and nuclear factor kappa B (NF-κB). Hematoxylin and eosin-stained sections of stomach, intestine, and brain tissues were examined using light microscopy...
January 1, 2018: Journal of International Medical Research
https://www.readbyqxmd.com/read/29751773/an-unusual-finding-in-a-desmoid-type-fibromatosis-of-the-pancreas-a-case-report-and-review-of-the-literature
#5
Joseph Clarence Torres, Chen Xin
BACKGROUND: Desmoid-type fibromatoses are rare benign and fibrous tumors that account for approximately 0.03% of total neoplasms. Within this category of neoplasms, pancreatic desmoid-type fibromatosis is an extremely rare subgroup, accounting for approximately 5% of desmoid-type fibromatoses. Although the etiology is unknown, some risk factors include trauma, surgery, family history of desmoid tumor, pregnancy, use of contraceptives, genetic mutation, and familial adenomatous polyposis or Gardner syndrome...
May 12, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29744791/olanzapine-as-antiemetic-drug-in-oncology-a-retrospective-study-in-non-responders-to-standard-antiemetic-therapy
#6
Florian Slimano, Florence Netzer, Isabelle Borget, François Lemare, Benjamin Besse
Background The role of olanzapine in the treatment of chemotherapy-induced nausea and vomiting (CINV) in addition to the antiemetic therapeutic combination with aprepitant, setrons, and corticosteroids has not been well defined. Objective To investigate the effectiveness of the addition of olanzapine to a standard triplet therapy for the prevention of CINV in patients who experienced CINV during their first chemotherapy course, despite receiving a well-managed prevention protocol. Setting One comprehensive cancer centre in France...
May 9, 2018: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/29743140/a-phase-i-single-arm-open-label-dose-escalation-study-of-intraperitoneal-cisplatin-and-doxorubicin-in-patients-with-recurrent-ovarian-cancer-and-peritoneal-carcinomatosis
#7
Clemens B Tempfer, Urs Giger-Pabst, Veronika Seebacher, Miriam Petersen, Askin Dogan, Günther A Rezniczek
OBJECTIVE: We performed a phase I, single-arm, non-randomized, open-label, dose-escalation trial to determine the dose-limiting toxicity of intraperitoneal cisplatin and doxorubicin applied as pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with recurrent ovarian cancer. METHODS: We used a standard 3 + 3 dose-escalation design with doxorubicin 1.5 mg/m2 , cisplatin 7.5 mg/m2 q 4 to 6 weeks for 3 cycles and subsequent dose escalation steps (20% increment per step) in patients with recurrent ovarian cancer and peritoneal carcinomatosis...
May 6, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29743043/phase-ii-study-of-adjuvant-chemotherapy-with-s1-plus-oxaliplatin-for-chinese-patients-with-gastric-cancer
#8
Guoxiu Wang, Jiuda Zhao, Yan Song, Wen Zhang, Yongkun Sun, Aiping Zhou, Jing Huang, Feng Du, Lin Yang
BACKGROUND: S-1 plus oxaliplatin(SOX) has been demonstrated to be effective and well tolerated for patients with metastatic gastric cancer. We conducted this phase II study to evaluate the feasibility of SOX as adjuvant chemotherapy for gastric cancer after curative resection. METHODS: Adjuvant chemotherapy consisted of six to eight cycles of S-1 plus oxaliplatin. Oxaliplatin was administered intravenously at a dose of 130 mg/m2 on day 1. S-1 was administered orally at a dose of 70 mg/m2 daily from day 1 to 14 of a 3-week cycle...
May 9, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29731507/primary-papillary-serous-carcinoma-of-the-fallopian-tube-presenting-as-a-vaginal-mass-a-case-report-and-review-of-the-literature
#9
Einav Kadour-Peero, Lena Sagi-Dain, Gil Cohen, Roman Korobochka, Abed Agbarya, Jacob Bejar, Shlomi Sagi
BACKGROUND There is now evidence to support that some cases of high-grade serous papillary carcinoma arise from the fallopian tubes rather than the ovaries. Common symptoms at presentation include abdominal pain and swelling, vomiting, altered bowel habit and urinary symptoms. To our knowledge, this is the first case of serous papillary carcinoma presenting as a vaginal mass lesion. CASE REPORT A 41-year-old woman was referred to the Bnai-Zion Medical Center with the main complaint of irregular vaginal bleeding, vaginal mucous discharge, and suspected pelvic mass...
May 7, 2018: American Journal of Case Reports
https://www.readbyqxmd.com/read/29725799/the-timeliness-of-patients-reporting-the-side-effects-of-chemotherapy
#10
Ian Olver, Mariko Carey, Allison Boyes, Alix Hall, Natasha Noble, Jamie Bryant, Justin Walsh, Rob Sanson-Fisher
PURPOSE: To explore the actions cancer patients reported they would take in response to a range of common side effects of chemotherapy and whether these were considered appropriate based on current guidelines and evidence; and to explore the sociodemographic and cancer-related variables associated with patients selecting the appropriate action (immediate medical attention or reporting) for two potentially life-threatening side effects: fever, and unusual bleeding and bruising. METHODS: Four hundred thirty-six medical oncology and haematology patients receiving chemotherapy completed two surveys to provide demographic, disease and treatment characteristics, and details on how they would respond if they experienced a range of specified side effects of chemotherapy (for example, nausea and vomiting, fatigue, and skin rash or nail changes)...
May 3, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29724299/comparison-of-antiemetic-effects-of-granisetron-and-palonosetron-in-patients-receiving-bendamustine-based-chemotherapy
#11
M Uchida, T Nakamura, Y Makihara, K Suetsugu, H Ikesue, Y Mori, K Kato, M Shiratsuchi, K Hosohata, T Miyamoto, K Akashi
The antiemetic effects and safety of granisetron and palonosetron against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy. A total of 61 patients were eligible for this study. Before starting the bendamustine-based chemotherapy, granisetron or palonosetron were intravenously administered with or without aprepitant and/or dexamethasone. The proportions of patients with complete control (CC) during the overall (during the 6 days after the start of the chemotherapy), acute (up to 2 days), and delayed (3 to 6 days) phases were assessed...
May 1, 2018: Die Pharmazie
https://www.readbyqxmd.com/read/29722791/phase-3-safety-study-of-intravenous-nepa-a-novel-fixed-antiemetic-combination-of-fosnetupitant-and-palonosetron-in-patients-receiving-highly-emetogenic-chemotherapy
#12
L Schwartzberg, E Roeland, Z Andric, D Kowalski, J Radic, D Voisin, G Rizzi, R Navari, R J Gralla, Meinolf Karthaus
Background: NEPA, an oral fixed combination of the NK1RA netupitant (300mg) and clinically/pharmacologically distinct 5-HT3RA palonosetron (PALO, 0.50mg), is the first fixed antiemetic combination to have been approved. A single oral NEPA capsule plus dexamethasone (DEX) given prior to AC and non-AC highly emetogenic chemotherapy (HEC) showed superior prevention of chemotherapy-induced nausea and vomiting (CINV) over PALO plus DEX for 5 days post-chemotherapy. The safety of NEPA was well-established in the Phase 2/3 clinical program in 1169 NEPA-treated patients...
May 2, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29709740/retrospective-analysis-of-the-clinical-characteristics-therapeutic-aspects-and-prognosis-factors-of-18-cases-of-childhood-pineoblastoma
#13
Yongji Tian, Raynald Liu, Junji Qin, Junmei Wang, Zhenyu Ma, Jian Gong, Chunde Li
Pineoblastoma is a rare malignant tumor of the pineal gland, which is more common in children. We retrospectively reviewed 18 cases of pineoblastoma in children (10 girls), including general, clinical, and therapeutic information, and factors affecting prognosis. The median age of the children was 51.7 months (19-156 mo). Presenting symptoms included vomiting (64.70%), headache (47.06%), weak or unsteady walking (35.29%), and nausea (29.41%). Rarer symptoms (one patient each) included limb rigidity, inability to speak, double vision, fever, and Parinaud's syndrome...
April 27, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29702540/safety-of-dexamethasone-for-nausea-and-vomiting-prophylaxis-in-children-receiving-hematopoietic-stem-cell-transplantation
#14
Edric Paw Cho Sing, Tal Schechter, Muhammad Ali, Lillian Sung, L Lee Dupuis
BACKGROUND: Many children undergoing hematopoietic stem cell transplantation (HSCT) experience chemotherapy-induced nausea and vomiting (CINV) despite receiving prophylaxis. Guideline-consistent CINV prophylaxis includes dexamethasone, but uncertainty with regard to safety potentially limits the use of dexamethasone in children. We describe immediate adverse events (AEs) attributable to dexamethasone given for CINV prophylaxis to children during HSCT conditioning. MATERIALS AND METHODS: Children enrolled in a previous prospective study were retrospectively analyzed...
April 26, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29697417/chinese-herbal-medicines-in-the-prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomiting
#15
Chang Lv, Chengjin Shi, Lifen Li, Xuesen Wen, Cory J Xian
PURPOSE OF REVIEW: Chemotherapy-induced nausea and vomiting (CINV) critically impact on cancer patients' quality of life, causing various complications, and increasing the risk of chemotherapeutic failure. Current treatments addressing CINV are reasonably costly and have many side effects. Chinese herbal medicines (CHMs) have been widely used in treating CINV in China. Clinical trials and modern experimental studies on CINV using CHMs are reviewed for clues that may help us to better prevent and treat CINV with CHMs, and develop safe and effective treatments...
April 24, 2018: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/29696478/concurrent-chemoradiation-for-locally-advanced-stage-iii-non-small-cell-lung-cancer-with-cisplatin-vinorelbine-and-thoracic-radiotherapy-a-phase-ii-study-from-the-galician-lung-cancer-group
#16
M Costa Rivas, G Huidobro Vence, J L Fírvida Pérez, B Campos Balea, J García Gonzalez, M Lázaro Quintela, M Caeiro Muñoz, B Taboada Valladares, J E Castro Gómez, S Vázquez Estevez, F J Afonso Afonso, C Azpitarte Raposeiras, M Amenedo Gancedo, J Casal Rubio
PURPOSE: The aim of this phase II study was to evaluate the activity and safety of the combination of cisplatin and vinorelbine with thoracic radiotherapy in unresectable locally advanced stage III non-small cell lung cancer (NSCLC). The primary endpoint was the objective response rate (ORR). Secondary objectives included toxicity profile, progression-free survival (PFS), and overall survival (OS). MATERIALS AND METHODS: A total of 48 NSCLC patients were enrolled (median age 60 years, 52% stage IIIA and 48% stage IIIB, 52% adenocarcinoma)...
April 25, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29693712/effects-of-rolapitant-administered-intravenously-on-the-pharmacokinetics-of-a-modified-cooperstown-cocktail-midazolam-omeprazole-warfarin-caffeine-and-dextromethorphan-in-healthy-subjects
#17
Xiaodong Wang, Zhi-Yi Zhang, Sujata Arora, Jing Wang, Sharon Lu, Dan Powers, Vikram Kansra
Rolapitant is a selective, long-acting neurokinin-1 receptor antagonist, approved in the United States and Europe for prevention of delayed chemotherapy-induced nausea and vomiting in adults. This open-label study evaluated the effects of a new intravenous formulation of rolapitant on cytochrome P450 (CYP) enzyme (CYP3A, CYP1A2, CYP2C9, CYP2C19, and CYP2D6) activity. On days 1 and 14, 36 healthy volunteers received a modified Cooperstown cocktail (midazolam 3 mg [CYP3A substrate], caffeine 200 mg [CYP1A2 substrate], S-warfarin 10 mg [CYP2C9 substrate] + vitamin K 10 mg, omeprazole 40 mg [CYP2C19 substrate], and dextromethorphan 30 mg [CYP2D6 substrate])...
April 25, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29690798/acute-chemotherapy-induced-nausea-and-vomiting-in-children-with-cancer-still-waiting-for-a-common-consensus-on-treatment
#18
Antonio Ruggiero, Daniela Rizzo, Martina Catalano, Paola Coccia, Silvia Triarico, Giorgio Attiná
Chemotherapy-induced nausea and vomiting (CINV) is one of the most common treatment side-effects, and remains a significant concern, in children undergoing chemotherapy. Although adult patients receive chemotherapy regimens combined with appropriate standardized antiemetic treatment, children can receive markedly varying antiemetic treatments. A narrative review of CINV was performed regarding CINV definition, scoring system, prevention and treatment, specifically focussing on studies conducted with paediatric oncology patients...
January 1, 2018: Journal of International Medical Research
https://www.readbyqxmd.com/read/29682620/a-prospective-cohort-study-of-patient-reported-vomiting-retching-nausea-and-antiemetic-use-during-neoadjuvant-long-course-radiation-therapy-and-concurrent-5-fluorouracil-based-chemotherapy-for-rectal-adenocarcinoma
#19
Kristopher Dennis, Liang Zeng, Carlo De Angelis, Hans Chung, Natalie Coburn, Edward Chow, C Shun Wong
Background and purpose: Antiemetic guidelines suggest daily prophylaxis with a serotonin3 receptor antagonist (5-HT3 RA) as an option for patients receiving long-course neoadjuvant radiation therapy and concurrent 5-fluorouracil-based chemotherapy for rectal cancer, despite the risks that 5-HT3 RA-induced constipation may pose. We explored the incidence of patient-reported vomiting, retching, nausea and antiemetic intake among patients in this setting to determine if these risks are justified...
March 2018: Clinical and Translational Radiation Oncology
https://www.readbyqxmd.com/read/29682436/metastatic-sternal-osteosarcoma-a-rare-tumor
#20
Muhammad Masab, Ena Arora, Sorab Gupta, Hafsa Farooq, Vishal Jindal, Shorabh Sharma
Osteosarcoma is the most common primary malignant tumor of the long bones. However, primary osteosarcoma of the chest wall, particularly the sternum, is an extremely rare occurrence. We report a 36-year-old male presenting with a hard, immobile, palpable, anterior chest wall mass. A computed tomographic (CT) scan showed a large destructive anterior mediastinal mass involving the manubrium and sternum with multiple bilateral calcified lung masses, pleural effusions and partially calcified aortopulmonary, right hilar and subcarinal lymphadenopathy...
February 19, 2018: Curēus
keyword
keyword
107786
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"